MERCK & CO, INC. for MERCK & CO INC
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Issues related to, Tax Reform, Generally; Tax Cuts and Jobs Act of 2017 (P.L. 115-97)
| Lobbyist | Covered position, as disclosed |
|---|---|
| ADAM HUFTALEN | — |
| BRADLEY ALLEN ROSSIN | — |
Health Issues HCR
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 19, Lower Costs, More Cures Act of 2019 H.R. 133, Consolidated Appropriations Act of 2021, including provision relating to vaccine funding and vaccinations H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. including provisions relating to Anti-microbial Resistance H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 6197, Increasing Access to Biosimilars Act of 2020 H.R. 8061, Community Immunity During COVID-19 Act of 2020 H.R. 8920, The Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2020 S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 4760, The Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act 2020 Issues relating to, 340B Reforms; 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340 drug pricing program; Drug pricing; Anti-microbial Resistance; Biosimilars; Maternal Health; Cost and value of medicines; Vaccines; Supply chain; COVID-19 vaccines; COVID-19 issues; Vaccines catch up; General pharmaceutical issues; Average Manufacture Price (AMP) cap; Executive Order 13937, Access to Affordable Life-Saving Medications; Department of Agriculture Center for Veterinary Biologics (CVB) funding.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ERIN DARLING | — |
| ROBERT FILIPPONE | — |
| ADAM HUFTALEN | — |
| COREY MALMGREN | — |
| BRADLEY ALLEN ROSSIN | — |
| ELIZABETH SCHWARTZ | — |
Medicare/Medicaid MMM
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019, including provisions relating to AMP cap and Medicare Part D rebate Issues relating to, Medicaid; Medicare; Medicare Part B; Medicare Part B and D drug pricing issues; 340B reforms; 340B program integrity; 340B of the Public Health Services Act; 340B drug pricing issues; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid demonstrations.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ERIN DARLING | — |
| ROBERT FILIPPONE | — |
| ADAM HUFTALEN | — |
| COREY MALMGREN | — |
| BRADLEY ALLEN ROSSIN | — |
| ELIZABETH SCHWARTZ | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.